Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) is one of the top penny stocks to buy in investors’ stock portfolio . On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 price target.

The research firm remains confident about the company’s outlook, impressed by the real-world presentation at ASCO that broadened the commercial and clinical case of candidate drug Amtagvi. The presentations reiterated the drug’s efficacy, safety, and workflow data in the treatment of adults with advanced, unresectable, or metastatic melanoma.

According to Citizens, the presentations affirmed the need for patients to be referred to an adoptive T-cell therapy center before the disease burden becomes severe. Iovance has already started advancing in non-small cell lung cancer, sarcoma, and first-line melanoma.

Chief Executive Officer Frederick Vogt has already reiterated plans to accelerate the adoption and commercial expansion of Amtagvi amid record-high market demand. The company is also positioned for long-term revenue growth, as it has advanced multiple ongoing and new clinical trials.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company pioneering tumor-infiltrating lymphocyte (TIL) therapies to treat cancer. By harvesting and multiplying a patient’s own immune cells, they create personalized immunotherapies designed to recognize and destroy solid tumors.

While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks .